heiDATA

Metrics

167,578 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Publication Year: 2023

41 to 50 of 2,559 Results

Vardarli_Suppl Fig 47.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.8 KB - MD5: a8a02f96648251f36d57cec66aac29e1 Suppl. Fig. 47. Funnel plot for trials investigating insulin-dependent diabetes mellitus any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 46.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 71.7 KB - MD5: 7e83c6d464b3338702449c8b9f24491b Suppl. Fig. 46. Galbraith plot for trials investigating adrenal insufficiency grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 45.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 68.4 KB - MD5: d78f68109278d4cd9cce0b16cc721242 Suppl. Fig. 45. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 44.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 67.2 KB - MD5: cd781c30f0006a4ad7f171b926a376a0 Suppl. Fig. 44. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 43.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.6 KB - MD5: 753d4e08425c46578df825f5e795a91c Suppl. Fig. 43. Funnel plot for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 42.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 70.1 KB - MD5: b5a0ac42aea01ae65c1000f3ad49c2b0 Suppl. Fig. 42. Galbraith plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 41.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.2 KB - MD5: ad6c63c17fd489fa8c647b90891930e3 Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 40.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 67.1 KB - MD5: 23a3912a62f8977ad3197d69d3b0cd41 Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 4.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 81.0 KB - MD5: df108cf5375705ae0e54343a1fb8acac Suppl. Fig. 4. Forest plot for cumulative meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 39.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.4 KB - MD5: 5bf15c23af6441a53ca79acff68d604c Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 47.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 64.8 KB -

Suppl. Fig. 47. Funnel plot for trials investigating insulin-dependent diabetes mellitus any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 46.pdf

Adobe PDF - 71.7 KB -

Suppl. Fig. 46. Galbraith plot for trials investigating adrenal insufficiency grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 45.pdf

Adobe PDF - 68.4 KB -

Suppl. Fig. 45. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 44.pdf

Adobe PDF - 67.2 KB -

Suppl. Fig. 44. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 43.pdf

Adobe PDF - 64.6 KB -

Suppl. Fig. 43. Funnel plot for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 42.pdf

Adobe PDF - 70.1 KB -

Suppl. Fig. 42. Galbraith plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 41.pdf

Adobe PDF - 64.2 KB -

Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 40.pdf

Adobe PDF - 67.1 KB -

Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 4.pdf

Adobe PDF - 81.0 KB -

Suppl. Fig. 4. Forest plot for cumulative meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 39.pdf

Adobe PDF - 64.4 KB -

Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications